Hughes syndrome crosses boundaries (Q35172192)

6 August 2017

1 reference

title

Hughes syndrome crosses boundaries (English)

1 reference

6 August 2017

author

Guillermo Ruiz-Irastorza

series ordinal

1

object named as

Guillermo Ruiz-Irastorza

1 reference

6 August 2017

2

Munther A Khamashta

1 reference

6 August 2017

3

Graham R V Hughes

1 reference

6 August 2017

publication date

1 February 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

1-2

1 reference

6 August 2017

page(s)

43-48

1 reference

Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Validation of the Sapporo criteria for antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies in an unselected stroke population

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Diagnostic testing for coagulopathies in patients with ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Cerebrovascular ischemic events with high positive anticardiolipin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Warfarin for multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Treatment of the antiphospholipid syndrome in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900005-2

7 January 2021

10.1016/S1568-9972(01)00005-2

Identifiers

DOI

1 reference

6 August 2017

1 reference